Rituximab (Rituxan) — Clinical Reference

Administration Protocols

• First infusion: Start at 50 mg/hr; increase by 50 mg/hr every 30 min as tolerated; max 400 mg/hr.
• Subsequent infusions: Can start at 100 mg/hr if prior infusion was well tolerated; max 400 mg/hr.
• Always administer as an IV infusion — do not give as IV push or bolus.

• Antipyretic (acetaminophen)
• Antihistamine (diphenhydramine)
• Corticosteroid (methylprednisolone 100 mg IV or equivalent) — especially before first infusion

⚠️ Special Warnings & Precautions

1. Fatal Infusion Reactions (Black Box Warning)

• Fatal infusion reactions have been reported within 24 hours of administration.
• ~80% of fatal reactions occurred with the first infusion.
• Symptoms: hypotension, bronchospasm, angioedema, urticaria, hypoxia.
• Action: Monitor continuously during infusion; have resuscitation equipment readily available. Discontinue immediately for severe reactions.

2. Tumor Lysis Syndrome (TLS) (Black Box Warning)

• Can occur within 12–24 hours after the first infusion, particularly in patients with high tumor burden (e.g., CLL, high-grade lymphoma).
• Prophylaxis: hydration, allopurinol/rasburicase before infusion.

3. Severe Mucocutaneous Reactions (Black Box Warning)

• Stevens-Johnson syndrome, toxic epidermal necrolysis, lichenoid dermatitis, vesiculobullous dermatitis — some with fatal outcomes.
• Discontinue Rituximab in patients experiencing these reactions.

4. Progressive Multifocal Leukoencephalopathy (PML) (Black Box Warning)

• Caused by JC virus reactivation — often fatal.
• Monitor for new or worsening neurological symptoms.
• Discontinue and initiate workup (brain MRI, CSF PCR for JC virus) if suspected.

5. Hepatitis B Virus (HBV) Reactivation (Black Box Warning)

• Screen all patients for HBV before initiating therapy (HBsAg, anti-HBc, anti-HBs).
• Reactivation can cause fulminant hepatitis and death.
• Prophylactic antiviral therapy required for HBsAg+ patients; monitor HBV-DNA in anti-HBc+ patients.

6. Infections

• Increased risk of serious bacterial, viral, and fungal infections.
• Delay administration in patients with active infections.
• Consider PCP prophylaxis, especially when combined with corticosteroids or chemotherapy.

7. Cardiovascular

• Arrhythmias (including ventricular fibrillation) and angina during infusion have been reported.
• Use with caution in patients with pre-existing cardiac conditions; monitor during and after infusion.

8. Bowel Obstruction / Perforation

• Rare but reported — particularly in patients with abdominal lymphoma.

9. Immunization

• Do not administer live vaccines to patients receiving Rituximab.
• Ideal to complete vaccinations at least 4 weeks (live vaccines) or 2 weeks (inactivated vaccines) before starting therapy.
• Antibody responses to vaccines may be impaired for months after treatment due to prolonged B-cell depletion.

Required Laboratory Tests

Before Initiation:

During & After Treatment:

Key Populations Requiring Extra Caution

• Elderly / debilitated patients: Higher risk of severe infusion reactions and infections; benefit-risk must be carefully weighed.
• HIV-positive patients: Severely immunocompromised; PML and opportunistic infections risk markedly elevated.
• Pregnancy: Category C — avoid unless benefit clearly outweighs risk; may cause neonatal B-cell depletion.
• Autoimmune bullous diseases (BP, pemphigus): RA protocol (2 × 1g, 2 weeks apart) is recommended; benefit in Bullous Pemphigoid may be less pronounced than in pemphigus.

Sources: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy (p. 60); Management of Bullous Pemphigoid (p. 11); FDA Prescribing Information (Rituxan).

Rituximab in a Diabetic + Hypertensive Patient

🩸 Diabetes-Specific Considerations

1. Corticosteroid Pre-medication — Major Concern

• Acute hyperglycemia — often sharp rise 4–8 hours post-infusion
• Worsening of glycemic control for 24–48 hours post-dose

In the Lupus Nephritis (LN) protocol, patients received methylprednisolone 500 mg IV with Rituximab — this would cause extreme glucose excursions in diabetic patients and necessitates intensive glucose monitoring (Management of Glomerular Diseases, p. 218).

2. Infection Risk — Compounded

• Diabetes independently increases infection susceptibility.
• Combined with Rituximab-induced B-cell depletion → significantly elevated risk of bacterial, fungal, and opportunistic infections.
• PCP prophylaxis (trimethoprim-sulfamethoxazole or equivalent) should be strongly considered.
• Vigilant wound surveillance and foot care counseling.

3. Renal Function

• Diabetic nephropathy may already compromise renal reserve.
• Tumor Lysis Syndrome (in oncology settings) is more dangerous with pre-existing CKD.
• Monitor eGFR, creatinine, and electrolytes more frequently.

4. Delayed Healing / Skin Reactions

• Mucocutaneous reactions (a black-box warning) are harder to detect and manage in diabetic patients with neuropathy or compromised skin integrity.

💉 Hypertension-Specific Considerations

1. Infusion-Related Blood Pressure Changes

• Rituximab infusion reactions can cause both hypotension (anaphylactoid) and hypertension (cytokine release).
• In a hypertensive patient:
  • Baseline BP must be recorded before infusion
  • Monitor BP every 15–30 minutes during the first infusion, every 30–60 min subsequently
  • Hold/slow infusion for BP >180/110 mmHg or significant drops

2. Corticosteroid Pre-medication — BP Effect

• IV methylprednisolone causes transient BP elevation (sodium retention, sympathetic activation).
• In a poorly controlled hypertensive patient, ensure antihypertensives are taken on infusion day (with a small sip of water if NPO).
• Avoid withholding AM antihypertensive doses before infusion.

3. Cardiovascular Monitoring

• Rituximab carries a risk of arrhythmias, angina, and rarely MI during infusion.
• Hypertensive patients — especially those with LVH or ischemic heart disease — are at higher baseline cardiovascular risk.
• ECG before each cycle in patients with significant cardiac history.
• Have crash cart and resuscitation equipment available.

4. NSAID / ACEI Interaction Watch

• If patient is on ACE inhibitors or ARBs for hypertension: these can potentiate hypotensive infusion reactions to Rituximab.
• Some protocols recommend withholding ACE inhibitors/ARBs 12–24 hours before each Rituximab infusion (discuss with cardiology/nephrology).

📋 Additional Lab Tests Specific to This Patient

Summary: Key Adjustments for This Patient